The Lynx Group
Cholangiocarcinoma News

Highlights from the 3rd Annual CCA Summit

A Global Perspective on CCA
Videos — January 14, 2022
Dr Virote Sriuranpong provides a perspective on key issues facing Thailand and other Asian countries in the prevention, screening, and early diagnosis of CCA.
Read More

Molecular Targets in iCCA Surgical Candidates
Videos — January 14, 2022
Drs Keri Lunsford and Alice Wei provide their perspectives on how the molecular profile of iCCA patients can help direct surgery and locoregional therapy.
Read More

Periadjuvant Therapy in iCCA
Videos — January 14, 2022
Dr Cristina Ferrone discusses the use of adjuvant therapy, and Dr Shishir Kumar Maithel speaks to the role of neoadjuvant therapy in patients with iCCA.
Read More

New Frontiers in Surgery for CCA
Videos — January 14, 2022
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Read More

Transplantation in iCCA
Videos — January 14, 2022
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Potential therapeutic targets for cholangiocarcinoma (CCA) include oncogenic pathways and other options, such as epigenetics, posttranslational modifications, and metabolism, according to presentations delivered during Session I, “Advances in Translational/Molecular Targets in CCA: New Molecular Targets/Pathways in CCA,” at the 3rd Annual CCA Summit.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Cholangiocarcinoma (CCA) involves genetic heterogeneity, highlighting the need to identify new inherited variants, as discussed at the 3rd Annual CCA Summit in Session II, “Molecular Epidemiology of CCA.”
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Personalization of therapy and novel regimens are needed to improve options for patients with cholangiocarcinoma (CCA).
Read More

December 2021, Vol 2, No 4 — January 5, 2022
Improved understanding of predictive biomarkers is needed in immuno-oncology, and various immunotherapy combinations using different mechanisms of action are being investigated in cholangiocarcinoma (CCA) and other biliary tract cancers, according to presentations delivered at Session IV, “What’s New in Immuno-­oncology in BTC? Monotherapy and Combo Therapies,” at the 3rd Annual CCA Summit.
Read More

December 2021, Vol 2, No 4 — January 5, 2022
New biomarker technologies may be combined with cholangiocarcinoma (CCA) characteristics to predict patient response to treatment, according to presenters at Session V, “Biomarker Testing in CCA: New Technologies/­Imaging as a Biomarker,” during the 3rd Annual CCA Summit.
Read More

Page 1 of 3


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: